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Dysentery  as a rare GI  symptom found  in  COVID-19
patients
La  disentería  como  síntoma  digestivo  poco  frecuente  que se  encuentra  en
los  pacientes  con  COVID-19
Coronavirus  Disease  2019  (COVID-19)  caused  by  SARS-CoV-2
first  started  in Wuhan,  China,  and soon  turned  to  a  pan-
demic  and  still  continue  to  spread  across  the  world.1,2 With
an  increasing  number  of  COVID-19  cases  outside  of  China,
Table  1  Serial  laboratory  results  of  43-year-old  woman  with  presentation  of dysentery  due  to  the  infection  with  SARS-CoV-2.
Blood  biochemistry  Serology,  endocrinology  and  tumor  marker  ESR  1 h,
mm/h
21a 0--20
Test,  unit  Result  Reference
range
Test,  unit Result  Reference
range
FBS,  mg/dL  109 70--99
Diabetic:
>126





1.54a 0.7--1.4  Ferritin,
ng/mL






0.36a 0--0.3 AFP  (Clia),
IU/mL








30  11--37  CEA  (Clia),
IU/mL










89  40--120  RBC,  106̂/L  4.31  4.5--5.9
TIBC, g/dL  419 230--440  Test,  Unit  Result  Reference
range
Hb,  g/dL  13.80  13.5--17.5





LDH  400  Up  to  300  Platelet,
103̂/L
92.6  80--100
Abbreviation: FBS: Fasting Blood Sugar; AST: Aspartate Amino Transferase; ALT: Alanine Transferase; TIBC: Total Iron-Binding Capacity;
Hb A1c: Glycosylated Hemoglobin; CRP: C-Reactive Protein; AFP: Alpha-Fetoprotein; CEA: Embryonic Carcinoma Antigen; LDH: Lactate
Dehydrogenase; WBC: White Blood Cell; RBC: Red Blood Cell; Hb:  Hemoglobin.
a Higher in comparison to the reference value.
our  clinics  in  Shahid  Beheshti  Hospital,  Qom  city,  was  faced
with  a  large  number  of  patients  who  were  suspected  of
being  infected  with  the SARS-CoV-2.  Following  the outbreak
of  COVID-19,  the prevalence  of gastrointestinal  (GI) tract
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symptoms  significantly  goes  up. This  incidence  in COVID-19
patients  is  well  documented  in literatures.3 After  February
20,  2020,  the  day  that  Iran  reported  as  the start of COVID-19
outbreak,  the number  of patients  referred  to  our  GI  clinic
was  unusually  increased.  The  most  important  complaint  of
patients  was  the  incidence  of some  unusual  GI  symptoms
resistant  to  medication.4
One  of  the questions  that  need to  be  answered  promptly
is  that  whether  the  incidence  of  rare  GI  symptoms  is  pos-
sible  in  confirmed  COVID  pneumonia  patients.  The  answer
to  this  question  may  help physicians  take  better  diagnostic
and  therapeutic  approaches  for  patients  with  this  symptom.
Currently,  we have  reported  the  clinical  data  in  details  as
well  as  the  result  of  chest  CT of  a  COVID-19  patient  with
dysentery.
A  43-year-old  woman  was  referred  to  our  gastroenterol-
ogy  clinic,  complaining  from  dysentery  for  one  week.  She
did  not  mention  any  cough,  dyspnea  or  respiratory  disor-
ders.  Her  past  medical  history  was  unremarkable  and  she
ignored  smoking,  drinking  or  using  any  drugs  and  medica-
tions.  Respiratory  rate:  18  per  minute  and body  temperature
from  oral  root:  37.5--38 ◦C.  In order  to  accurately  evaluate
the  patient,  laboratory  test  was  performed.  The  results  are
summarized  in  (Table  1).  The  levels  of  CRP,  LDH  and  ESR
1 h  were  higher  than  the normal range  and  were  equal  to
8.4,  400  and  21  respectively.  Alkaline  phosphatase,  amylase
serum  and  bilirubin  values  of  the  patient  were in normal
range.  Medication  with  ciprofloxacine,  500  mg and  metro-
dinazole,  500 mg was  started  after  the  first  symptoms  of
dysentery,  to  reduce  the volume  of  diarrhea  and  severe
dehydration.  Due  to  the  persistence  of  diarrhea  and  the
lack  of  therapeutic  response  to  medications,  as  well  as  eval-
uation  for  the probability  of inflammatory  bowel  disease
(IBD)  in  the  patient,  colonoscopy  was  performed  which  was
resulted  in patchy  erythema  (Fig.  1).  Also,  pathological  find-
ing  was  associated  with  the infiltration  of  inflammation  cells
which  made  us  suspect  infectious  (viral)  colitis.  Since the
incidence  of  such GI  symptoms  coincided  with  the COVID-
Figure  1  Colonoscopy  finding  of  43-year-old  woman  with  presentation  of  dysentery  which  was  resulted  in  patchy  erythema.
Figure  2  Chest  CT scans  (transverse  plane)  of  43-year-old  woman  with  presentation  of  dysentery  due  to  the  infection  with
SARS-CoV-2.  Chest  CT  resulted  bilateral  peripheral  ground  glass,  crazy  paving  and  small  consolation  opacities.
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19  outbreak  in Iran,  and also  more  importantly  since  the
patients  reported  to  reside  in  high  risk  areas,  we  suspected
patients  to be  infected  by  SARS-CoV-2.  Therefore,  for  more
validation,  laboratory-confirmed  COVID  pneumonia  was  per-
formed  by  using SARS-CoV-2  conventional  polymerase  chain
reaction  assay  and  sequencing  of the polymerase  chain  reac-
tion  (PCR)  amplicons,  which  was  reported  to  be  positive  for
the  patient.  After performing  chest  CT  scan,  we noticed  the
bilateral  lung  involvement,  as  revealed  bilateral  peripheral
ground  glass,  crazy  paving  and small  consolation  opacities
(Fig.  2).  Patient  was  isolated  in a negative  pressure  room
for  one  week  and  underwent  medications  as  mentioned
above.
According  to  the  findings  of  Zou  et  al.,  about  the role  of
ACE-2  as  the  main  host  cell receptor  for  entrance  of  2019-
nCoV  to  cell and with  notice  to  the high  expression  of  ACE-2
receptor  in the oral cavity,  as  well  as  in  colon,  intestine
and  gallbladder  and  enriching  in epithelial  cells,  we  sup-
posed  that  this receptor  may  mediate  some  GI  symptoms
of  infected  patients.5 Previously,  epidemiologic  finding  of
Lai  et  al.,  demonstrated  that  among  adult  patients,  some
common  respiratory  symptoms  were  followed  by  diarrhea.3
Previously,  we reported  that  infected  patients  with  COVID-
19  can present  some unusual  GI  symptoms.4 These  symptoms
were  resistant  to  medications  and  in some  cases  without  any
medications,  they  subsided.
At  the  age  of  COVID-19  crisis,  in  some  patients,  GI  physi-
cians  may  face  rare  GI  symptoms  such as  dysentery,  hepatic
involvement  or  other  ones  in patients.  Therefore,  it  is  nec-
essary  that  all  GI  physicians  should  be  aware  of the possible
occurrence  of  these  symptoms  as  an  important  prognosis
of COVID  pneumonia.  Although,  in this letter  we  only doc-
umented  one  case  of  this  issue, at  the age  of  COVID-19,
all  rare  GI  symptoms  should  be  exactly  addressed  in new
referred  patients  to  GI  clinic.  Recording  and  investigation
of  these  symptoms  may  open  a  new  window  to  help  finding
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